Botanix Investor Centre

Botanix Pharmaceuticals is a clinical stage synthetic cannabinoid pharmaceutical company with a targeted pipeline of dermatology and antimicrobial products. Our goal is to unlock the true potential of synthetic cannabinoids for people around the world, with an evidence-first approach. Our shareholders are valued partners in our Company, so we invite you to explore our Investor Centre, subscribe to our email updates and we will keep you updated with our progress.

Share price


Change

December 9, 2019
September 17, 2019
January 31, 2019
November 15, 2018
August 13, 2018
April 9, 2018
November 13, 2017

Latest video

Boston Herald AMR op-ed

Co-founder, president and CEO of Venatorx Pharmaceuticals, Christopher…

Quarterly Activities Report and 4C Quarterly Cash Flow Report

Botanix (ASX:BOT) has today published its Quarterly Activities…

ABC News | Mask rules leads to rise in skin conditions

Skin specialists have reported an increase in people seeking…

Atopic Dermatitis Update + Presentation

Botanix Pharmaceuticals has today updated the market with plans…

Investor Conference Call

Botanix Pharmaceuticals President and Executive Chairman, Vince…

Ticker News Interview

Botanix Pharmaceutical’s (ASX:BOT) Executive Director, Matt…

Investor Presentation + Conference Call

Botanix Pharmaceuticals has today released an updated investor…

BTX 1801 Clinical Development Update

Botanix Pharmaceuticals has today released a comprehensive update…

Interested in investing? Check out our latest investor presentation.

Sign up to receive our latest news.

Processing...
Thank you! Your subscription has been confirmed. You'll hear from us soon.
ErrorHere